Brian Ung
Overview
Explore the profile of Brian Ung including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
105
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
McGarvey N, Ung B, Carattini T, Imanak K, Lee A, Campbell T, et al.
Adv Ther
. 2023 Aug;
40(10):4626-4638.
PMID: 37597153
Introduction: Patients with triple-class exposed relapsed/refractory multiple myeloma (RRMM) have poor outcomes with substantial healthcare costs. Idecabtagene vicleucel (ide-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell...
2.
Wu J, Pelletier C, Ung B, Tian M, Khilfeh I, Curtis J
J Comp Eff Res
. 2020 Jul;
9(11):767-779.
PMID: 32638609
Treatment switching and healthcare costs were compared among biologic-naive psoriasis patients initiating apremilast or biologics with ≥12 months pre-/post-index continuous enrollment in Optum Clinformatics™ Data Mart. After propensity score matching,...
3.
Jagannath S, Rifkin R, Gasparetto C, Toomey K, Durie B, Hardin J, et al.
Clin Lymphoma Myeloma Leuk
. 2020 Mar;
20(5):272-276.
PMID: 32144027
No abstract available.
4.
Wu J, Pelletier C, Ung B, Tian M, Khilfeh I, Curtis J
Adv Ther
. 2020 Mar;
37(5):2098-2115.
PMID: 32141018
Introduction: We compared treatment switch patterns and healthcare costs among biologic-naive patients with psoriatic arthritis (PsA) who initiated apremilast or biologics. Methods: A 1:2 propensity score match was used to...
5.
Hari P, Ung B, Abouzaid S, Agarwal A, Parikh K
Future Oncol
. 2019 Oct;
15(35):4045-4056.
PMID: 31625415
To compare real-world outcomes and costs among patients with newly diagnosed multiple myeloma receiving lenalidomide-only maintenance (Len-Mt) versus no maintenance after autologous hematopoietic stem cell transplantation. Time to next treatment...
6.
Wu J, Pelletier C, Ung B, Tian M
Curr Med Res Opin
. 2019 Sep;
36(1):169-176.
PMID: 31517542
Information on treatment costs for psoriatic arthritis (PsA) can be valuable for payers and providers who make treatment and formulary decisions. This study compared real-world treatment patterns and healthcare costs...
7.
Wu J, Pelletier C, Ung B, Tian M
J Med Econ
. 2019 Jan;
22(4):365-371.
PMID: 30652520
Objective: This study compared real-world treatment patterns and healthcare costs among biologic-naive psoriasis patients initiating apremilast or biologics. Methods: A retrospective cohort study was conducted using the Optum Clinformatics™ claims...
8.
Kim S, Signorovitch J, Yang H, Patterson-Lomba O, Xiang C, Ung B, et al.
Adv Ther
. 2018 Sep;
35(10):1564-1577.
PMID: 30209750
Introduction: nab-Paclitaxel plus gemcitabine (nab-P + G) and FOLFIRINOX (FFX) are among the most common first-line (1L) therapies for metastatic adenocarcinoma of the pancreas (MPAC), but real-world data on their...
9.
Gupta S, Abouzaid S, Liebert R, Parikh K, Ung B, Rosenberg A
Clin Lymphoma Myeloma Leuk
. 2018 Feb;
18(3):210-218.
PMID: 29429817
Background: The present study characterized the effect of multiple myeloma (MM) on work productivity, health care resource usage, and out of pocket costs (OOPCs) and examined the association of adherence...
10.
Fendt P, Ung B, Vogenberg F
Am Health Drug Benefits
. 2017 Dec;
10(8):424-426.
PMID: 29263775
No abstract available.